CA2232682A1 - Utilisation de la prolactine comme un antagoniste de tgf-beta - Google Patents

Utilisation de la prolactine comme un antagoniste de tgf-beta Download PDF

Info

Publication number
CA2232682A1
CA2232682A1 CA002232682A CA2232682A CA2232682A1 CA 2232682 A1 CA2232682 A1 CA 2232682A1 CA 002232682 A CA002232682 A CA 002232682A CA 2232682 A CA2232682 A CA 2232682A CA 2232682 A1 CA2232682 A1 CA 2232682A1
Authority
CA
Canada
Prior art keywords
tgf
prolactin
cells
cell
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002232682A
Other languages
English (en)
Inventor
Susan M. Richards
John M. Mcpherson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2232682A1 publication Critical patent/CA2232682A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention est fondée sur la découverte que la prolactine neutralise les effets du facteur de croissance tumorale .beta. (TGF-.beta.) sur les cellules. Un objet de la présente invention est un procédé de traitement d'un patient susceptible de souffrir d'une maladie ou d'une affection associée à la présence de TGF-.beta., par administration d'une dose efficace d'une composition pharmaceutiquement acceptable contenant de la prolactine.
CA002232682A 1996-04-30 1997-04-30 Utilisation de la prolactine comme un antagoniste de tgf-beta Abandoned CA2232682A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1649296P 1996-04-30 1996-04-30
US60/016,492 1996-04-30

Publications (1)

Publication Number Publication Date
CA2232682A1 true CA2232682A1 (fr) 1997-11-06

Family

ID=21777407

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002232682A Abandoned CA2232682A1 (fr) 1996-04-30 1997-04-30 Utilisation de la prolactine comme un antagoniste de tgf-beta

Country Status (5)

Country Link
EP (1) EP0921809A4 (fr)
JP (1) JP2000510112A (fr)
AU (1) AU2749697A (fr)
CA (1) CA2232682A1 (fr)
WO (1) WO1997040848A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597646B2 (en) 2005-10-25 2013-12-03 The Johns Hopkins University Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
EP1998810A4 (fr) 2006-03-13 2009-09-02 Univ Johns Hopkins Augmentation de la thromborésistance endothéliale
EP2083863B1 (fr) 2006-10-03 2015-03-18 Genzyme Corporation Anticorps contre le tgf-beta pour l'utilisation dans le traitement des nourrissons risquant de développer une dysplasie broncho-pulmonaire
TR201816180T4 (tr) 2010-03-12 2018-11-21 Genzyme Corp Meme kanserini tedavi etmek için kombinasyonlu tedavi.
WO2012090997A1 (fr) 2010-12-27 2012-07-05 京都府公立大学法人 CELLULES SPi ET LEUR PROCÉDÉ DE PRODUCTION
EP2737083A1 (fr) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Méthodes de diagnostic et de traitement du syndrome de myhre
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
WO2013100208A1 (fr) 2011-12-28 2013-07-04 京都府公立大学法人 Normalisation d'une culture de cellules endothéliales de la cornée
JPWO2015064768A1 (ja) 2013-10-31 2017-03-09 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
WO2016187312A1 (fr) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Procédés et compositions pour traiter une infection par alphavirus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0952846A1 (fr) * 1994-02-14 1999-11-03 Genzyme Corporation Prolactine servant d'adjuvant pour vaccin

Also Published As

Publication number Publication date
WO1997040848A1 (fr) 1997-11-06
EP0921809A4 (fr) 2001-10-24
JP2000510112A (ja) 2000-08-08
AU2749697A (en) 1997-11-19
EP0921809A1 (fr) 1999-06-16

Similar Documents

Publication Publication Date Title
Simorre-Pinatel et al. Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway.
Zhang et al. Umbilical cord-matrix stem cells induce the functional restoration of vascular endothelial cells and enhance skin wound healing in diabetic mice via the polarized macrophages
Cooper et al. Acceleration of onset of collagen‐induced arthritis by intra‐articular injection of tumour necrosis factor or transforming growth factor‐beta
US5612211A (en) Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
Libby et al. Production of platelet-derived growth factor–like mitogen by smooth-muscle cells from human atheroma
Gospodarowicz Growth factors and their action in vivo and in vitro
Limb et al. Cytokines in proliferative vitreoretinopathy
Roberts et al. The transforming growth factor-β s
Merwin et al. Transforming growth factor beta1 modulates extracellular matrix organization and cell‐cell junctional complex formation during in vitro angiogenesis
Righi et al. Monokine production by microglial cell clones
DE69914463T2 (de) Therapeutische chemokine rezeptor antagonisten
US7410639B2 (en) Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use
Dr. Weir et al. Macrophage colony‐stimulating factor release and receptor expression in bone cells
DE60103052T2 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
JP2006087434A (ja) 新規な神経栄養因子
US6133232A (en) Endoderm, cardiac and neural inducing factors
Hou et al. Astrogliosis in culture. IV. Effects of basic fibroblast growth factor
JP2002539082A (ja) 血管内皮増殖因子２
PT946199E (pt) Células sensíveis a ftcβ1 derivadas de medula óssea
CA2232682A1 (fr) Utilisation de la prolactine comme un antagoniste de tgf-beta
US20050032697A1 (en) Heparin binding VEGFR-3 ligands
EP0437281B1 (fr) Composition comprenant un facteur de croissance de fibroblaste acide (aFGF)
US8420780B2 (en) Mutated netrin 4, fragments thereof and uses thereof as drugs
US20080214463A1 (en) Method for cell adhesion and wound healing
DE69129113T2 (de) Stimulierung der stroma- und vorläuferzellen im knochenmark

Legal Events

Date Code Title Description
FZDE Dead